



NDA 208799

**NOTIFICATION OF
NON-COMPLIANCE WITH PREA**

Teva Pharmaceutical Industries Ltd.
c/o Teva Branded Pharmaceutical R&D, Inc.
145 Brandywine Parkway, Bldg. 300
West Chester, PA 19380

Attention: Michael Spitz
Senior Manager, Head of Respiratory, Oncology, Internal Medicine

Dear Mr. Spitz:

Please refer to your New Drug Application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (the Act) for AirDuo DigiHaler/AirDuo RespiClick (fluticasone propionate/salmeterol xinafoate inhalation powder), which was approved on January 27, 2017.

The Agency has determined that you have failed to meet the postmarketing requirements (PMR) of the Pediatric Research Equity Act (PREA) for this application because you have not yet submitted your pediatric assessment for PMRs 3155-1 and 3155-2, which were deferred until December 31, 2019. Therefore, we are hereby notifying you that due to your failure to submit either a pediatric assessment or a request for a deferral extension, you are not in compliance with federal law.

Under the provisions of section 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 355c(d)(1)], you must respond in writing within 45 calendar days of the date of this letter. Your response should include the reason(s) for the delayed pediatric assessment and a date by which you expect to submit the assessment. You may also include a request for a deferral extension, if applicable, which should be identified as a **"DEFERRAL EXTENSION REQUESTED"** in your response.

In accordance with the FD&C Act, FDA will post this letter and your response to the website at <https://www.fda.gov/drugs/development-resources/non-compliance-letters-under-505bd1-federal-food-drug-and-cosmetic-act> with redactions for any trade secrets and confidential commercial information 60 calendar days from the date of this letter.

Please identify your response to this letter as a **"RESPONSE TO PREA NON-COMPLIANCE LETTER."** To facilitate our review, submit this information to your NDA

with a cross-reference letter to the Investigational New Drug Application (IND) to which your protocol has been submitted.

If you have any questions, call Ngoc-Linh Do, Regulatory Project Manager, at (301) 348-1896.

Sincerely,

{See appended electronic signature page}

Sally Seymour, MD
Director
Division of Pulmonary, Allergy, and
Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

SALLY M SEYMOUR
01/30/2020 05:47:12 AM